Sanofi delivers solid 2012 results despite patent expirations
Commenting on the Group’s performance in 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “2012 was a turning point for Sanofi with the loss of exclusivity in the U.S. for several significant legacy drugs. Despite the effect of the patent cliff, Sanofi was able to grow sales and mitigate the impact on Business EPS1."
07 February 2013, 11:05 AM EST
Social Media Tools:
Click asset titles for downloads, embeds and more...
Subscribe via RSS
Journalists who register may create email subscriptions to search results and a cart of assets to download. Click here to login, register or edit profile.
What Our Users
"I like the way the DC is easy to navigate, easy to find stories, easy to find when they were filed so you know if they’re out of date, and easy to see an on-line version of the available video" -- Allan C Lee, Director of News and Current Affairs